Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis (APW-RSV)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01486758|
Recruitment Status : Completed
First Posted : December 6, 2011
Results First Posted : June 14, 2017
Last Update Posted : June 14, 2017
This trial is a proof-of-concept pilot study aim to investigate the biologic and clinical effects of early azithromycin treatment in children hospitalized with Respiratory Syncytial Virus (RSV) bronchiolitis.
In infants hospitalized with RSV bronchiolitis, azithromycin therapy (compared to placebo) will result in:
- Decreased concentrations of inflammatory mediators (IL-8 as primary outcome) in serum and nasal wash measured on day 8 after randomization.
- A smaller proportion of participants with recurrent (≥2) wheezing episodes during weeks 3-52 following randomization.
|Condition or disease||Intervention/treatment||Phase|
|RSV Bronchiolitis||Drug: Azithromycin Drug: Placebo||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Pilot Study: Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis|
|Study Start Date :||December 2011|
|Actual Primary Completion Date :||April 2014|
|Actual Study Completion Date :||May 2014|
Active Comparator: Azithromycin
Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.
Placebo Comparator: Placebo
- IL-8 Concentrations [ Time Frame: Day 8 ]Biological outcome: The difference in IL-8 concentrations, measured in serum on day 8 after randomization, among infants treated with azithromycin and those treated with placebo.
- Proportion of Participants Who Experience Subsequent Recurrent (≥2) Wheezing Episodes [ Time Frame: 3-52 weeks following randomization ]Clinical outcome: The difference in the proportion of participants who experience subsequent recurrent (≥2) wheezing episodes among infants treated with azithromycin and those treated with placebo.
- Concentrations of IL-8 in Nasal Lavage on Day 15 [ Time Frame: Day 15 ]
- Rates of Drug Related GI Side Effects. [ Time Frame: One month from randomization ]
- Likelihood to Develop 3 or More Wheezing Episodes [ Time Frame: Week 3-52 ]Likelihood to develop 3 or more wheezing episodes measured by a Kaplan-Meier survival analysis
- Respiratory Symptoms Following RSV Bronchiolitis [ Time Frame: 3-52 weeks following randomization ]Number of days with respiratory symptoms (cough, wheeze, or shortness of breath)
- Number of Children Who Were Prescribed Inhaled Corticosteroids [ Time Frame: 3-52 weeks following randomization ]
- Proportion of Participants With a Physician Diagnosis of Asthma [ Time Frame: Week 3-52 ]The proportion of participants with a physician diagnosis of asthma
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01486758
|United States, Missouri|
|Department of Pediatrics, Washington University School of Medicine; and St. Louis Children's Hospital|
|Saint Louis, Missouri, United States, 63110|
|Principal Investigator:||Avraham Beigelman, MD, MSCI||Washington University School of Medicine|